Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118025 | 0.84 | PTGS2 (0.43) | F10PTGS2 | |
| SCHEMBL7727831 | 0.84 | PTGS2 (0.43) | F10PTGS2 | |
| SCHEMBL7734225 | 0.82 | F10 (0.46) | F10PTGS2 | |
| SCHEMBL7732341 | 0.82 | F10 (0.46) | F10PTGS2 | |
| SCHEMBL7727260 | 0.82 | F10 (0.46) | F10PTGS2 | |
| SCHEMBL7727829 | 0.82 | F10 (0.46) | F10PTGS2 | |
| SCHEMBL7734355 | 0.80 | F10 (0.45) | F10PTGS2 | |
| SCHEMBL116673 | 0.79 | F10 (0.44) | F10PTGS2 | |
| SCHEMBL7722222 | 0.79 | F10 (0.44) | F10PTGS2 | |
| SCHEMBL116674 | 0.79 | F10 (0.44) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101609-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885PTGS2 1741/4885 |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 7/4885PTGS2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.